All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Our Co-Chair, Sagar Lonial, Winship Cancer Institute at Emory University, Atlanta, US, presents the results of the randomized phase III trial, E3A06, of lenalidomide versus observation alone in intermediate- and high-risk smoldering myeloma (SMM). This interview was conducted from ASCO 2019 in Chicago, US, where Professor Lonial also presented this data to a full audience. This trial has demonstrated, for the first time, that early intervention can prevent organ damage in SMM. One major difference in this study, compared to previous studies, was the use of modern imaging which identified and excluded patients with myeloma.
Take home message: high-risk SMM (as defined by Mayo 2018 or IMWG updated criteria) should receive early therapy. The study results, and Professor Lonial, recommend lenalidomide alone or lenalidomide in combination with dexamethasone.
Phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk SMM
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox